Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.34 Insider Own4.46% Shs Outstand69.00M Perf Week-5.22%
Market Cap162.84M Forward P/E- EPS next Y-0.37 Insider Trans0.00% Shs Float65.92M Perf Month8.26%
Income-22.40M PEG- EPS next Q-0.11 Inst Own9.67% Short Float0.40% Perf Quarter66.20%
Sales0.00M P/S- EPS this Y-18.54% Inst Trans- Short Ratio0.68 Perf Half Y151.06%
Book/sh0.22 P/B10.87 EPS next Y3.57% ROA-72.33% Short Interest0.27M Perf Year215.17%
Cash/sh0.31 P/C7.71 EPS next 5Y- ROE-92.40% 52W Range0.66 - 3.12 Perf YTD179.89%
Dividend Est.- P/FCF- EPS past 5Y16.52% ROI-149.98% 52W High-24.36% Beta1.03
Dividend TTM- Quick Ratio2.81 Sales past 5Y-20.00% Gross Margin- 52W Low257.03% ATR (14)0.24
Dividend Ex-Date- Current Ratio2.81 EPS Y/Y TTM1.69% Oper. Margin0.00% RSI (14)48.45 Volatility14.74% 9.03%
Employees- Debt/Eq0.01 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price8.34
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-23.72% Payout- Rel Volume7.65 Prev Close2.97
Sales Surprise- EPS Surprise-16.57% Sales Q/Q- EarningsMay 14 AMC Avg Volume389.06K Price2.36
SMA20-4.62% SMA5010.32% SMA20075.16% Trades Volume2,975,209 Change-20.54%
Date Action Analyst Rating Change Price Target Change
Apr-22-24Initiated H.C. Wainwright Buy $9
Jun-13-24 07:58AM
Jun-11-24 06:00AM
Jun-03-24 07:00AM
May-28-24 07:00AM
May-14-24 10:53PM
07:27AM Loading…
May-13-24 12:19PM
Apr-02-24 09:53AM
Mar-04-24 08:28PM
Feb-21-24 07:27AM
Feb-15-24 07:27AM
Jan-24-24 07:27AM
Jan-09-24 07:27AM
Dec-05-23 07:27AM
05:30AM Loading…
Nov-16-23 05:30AM
Nov-01-23 07:27AM
Oct-20-23 05:00PM
Oct-13-23 09:24AM
Oct-11-23 01:05PM
Oct-10-23 06:00AM
Sep-27-23 09:34AM
Sep-26-23 07:27AM
Sep-19-23 07:27AM
Aug-09-23 07:27AM
Aug-08-23 07:27AM
Jun-29-23 10:19AM
Jun-27-23 07:27AM
May-09-23 07:15AM
Mar-29-23 07:27AM
07:27AM Loading…
Mar-07-23 07:27AM
Jan-17-23 02:59PM
Dec-12-22 07:27AM
Nov-14-22 05:00PM
Nov-07-22 07:27AM
Oct-25-22 06:30AM
Oct-03-22 07:27AM
Sep-28-22 08:20AM
Sep-27-22 09:05AM
Aug-03-22 07:29AM
Jul-12-22 06:14AM
Jun-29-22 10:07AM
Jun-27-22 10:07AM
Jun-09-22 04:05PM
May-27-22 01:00PM
May-24-22 07:00AM
May-19-22 07:27AM
May-17-22 07:27AM
May-02-22 02:42PM
Mar-24-22 07:27AM
Mar-22-22 07:27AM
Mar-15-22 07:27AM
Mar-01-22 07:27AM
Feb-02-22 06:30AM
Jan-19-22 07:27AM
Nov-05-21 09:18AM
Nov-04-21 08:52AM
Nov-03-21 08:36AM
Nov-02-21 04:04PM
Oct-25-21 07:27AM
Oct-18-21 07:27AM
Sep-16-21 07:27AM
Sep-10-21 04:33PM
Sep-07-21 07:27AM
Aug-24-21 07:27AM
Aug-19-21 06:52AM
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.